EUVIMEDEUVIMED entdecken
Crossref

Visual outcomes after bevacizumab‐based therapy for optic pathway glioma

Benjamin I Siegel, Daniel Nelson, Jason H Peragallo, Tobey J MacDonald, David S Wolf

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Benjamin I Siegel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Bevacizumab, Optic Nerve Glioma, Visual Acuity, Visual Fields. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In optic pathway glioma (OPG), bevacizumab‐based therapy (BBT) has promising effects on radiographic tumor burden, but the impact on vision is less clear. This single‐institution study characterized visual acuity (VA) and visual field (VF) outcomes in 17 pediatric OPG patients treated with BBT. VA was stable or improved in 14 patients. Nine patients had evaluable VF data, six of whom experienced stability or improvement. Among six patients with vision deterioration as a treatment indication, stable or improved was observed for both VA and VF in five patients. In summary, BBT was associated with favorable visual outcomes in this cohort of patients with OPG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabOptic Nerve GliomaVisual AcuityVisual FieldsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansChildMaleFemaleAdolescentChild, PreschoolFollow-Up StudiesRetrospective StudiesPrognosis

Stichwörter der Autor:innen

Gliomaslow-gradeneuro-oncologyoutcomes research

Substanzen

BevacizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
  • Department of Ophthalmology, Emory University, Atlanta, Georgia, USA.
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Zitieren

APA

Siegel, B. I., Nelson, D., Peragallo, J. H., MacDonald, T. J., & Wolf, D. S. (2023). Visual outcomes after bevacizumab‐based therapy for optic pathway glioma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30668

Vancouver

Siegel BI, Nelson D, Peragallo JH, MacDonald TJ, Wolf DS. Visual outcomes after bevacizumab‐based therapy for optic pathway glioma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30668

BibTeX
@article{Siegel2023,
  author = {Siegel, Benjamin I and Nelson, Daniel and Peragallo, Jason H and MacDonald, Tobey J and Wolf, David S},
  title = {Visual outcomes after bevacizumab‐based therapy for optic pathway glioma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30668}
}
Kostenlos starten →